Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.

Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A
J Infect Dis. 2004 189 (10): 1811-20

PMID: 15122517 · DOI:10.1086/383277

To determine whether markers of T cell activation and maturation are independently predictive of the response to potent antiretroviral therapy, the Immunophenotypic Markers and Antiretroviral Therapy study applied a novel data-sharing strategy across 5 Adult AIDS Clinical Trial Group trials that counted naive and activated CD4(+) and CD8(+) T cells in 324 subjects. Regression models--adjustment for baseline CD4 cell count, human immunodeficiency virus (HIV) RNA, and study--revealed that high pretreatment CD8(+) T cell activation predicted virologic failure (P=.046). Additional models showed the greatest increase in CD4(+) T cell counts in subjects with highest pretreatment naive CD4(+) T cell counts (P<.0001), which was enhanced by high CD4(+) and low CD8(+) T cell activation. Total lymphocyte count also predicted a subsequent CD4(+) T cell change. These results document the utility of T cell markers in predicting treatment outcome and their potential value for the study and management of HIV-1 infection.

MeSH Terms (18)

Adult Anti-Retroviral Agents CD4 Lymphocyte Count CD8-Positive T-Lymphocytes Female Flow Cytometry Hemoglobins HIV-1 HIV Infections Humans Immunophenotyping Lymphocyte Activation Male Middle Aged Predictive Value of Tests Regression Analysis Reverse Transcriptase Polymerase Chain Reaction RNA, Viral

Connections (1)

This publication is referenced by other Labnodes entities: